<DOC>
	<DOCNO>NCT01399957</DOCNO>
	<brief_summary>Ampyra ( dalfampridine-ER ) approve FDA ( 2010 ) improve walk speed person multiple sclerosis . This project seek determine benefit take dalfampridine besides increase walk speed . This strictly observational study research staff involve decision stop start take medication .</brief_summary>
	<brief_title>Responsiveness Dalfampridine-ER Treatment Among Multiple Sclerosis Patients</brief_title>
	<detailed_description>Subjects evaluate start medication , throughout 14week period start D-ER well 12 18months follow start date medication regardless stayed medication .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Confirmed clinical diagnosis MS McDonald criterion Prescribed ampyra ( dalfampridine ) part usual care , yet start take medication baseline visit Receive MS care Mandell MS center Cognitively able understand direction complete protocol ( score 22 great MMSE ) 18 year age old Already begin take drug prior baseline research visit Not plan continue care Mandell Center least 14 week initiation therapy Unwilling unable complete assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Dalfampridine-ER</keyword>
	<keyword>Walking speed</keyword>
</DOC>